Teplizumab therapy for type 1 diabetes.

ABSTRACT:

Importance of the field

Type 1 diabetes mellitus (T1D) is a T-cell mediated autoimmune disease with selective destruction of beta cells. Immunological interventions are directed at arresting the loss of beta-cell function with the promise that this will make it easier for patients to control their glucose levels.

Areas covered in this review

This review provides a summary of the preclinical and clinical research published between 1992 and 2009 using teplizumab and other anti-CD3 antibodies to arrest the loss of beta-cell function in new onset T1D. Data from animal and human studies on the probable mechanism of action of teplizumab are also reviewed.

What the reader will gain

A broad perspective on the use of teplizumab in inducing disease specific tolerance.

Take h

SUBMITTER: Masharani UB 

PROVIDER: S-EPMC2825571 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature